Among these immune checkpoint inhibitors, tislelizumab, a monoclonal antibody targeting the programmed cell death protein 1 (PD-1), has shown particular promise and has received approval for the treatment of various malignancies, including esophageal cancer (3). Here, PDCD1 is linked to esophageal cancer.